Prosecution Insights
Last updated: November 04, 2026
Application No. 17/287,518

SYSTEM FOR RECOGNITION OF BIOLOGICAL ALTERATION IN HUMAN TISSUES

Final Rejection §112
Filed
Apr 22, 2021
Priority
Oct 29, 2018 — EU 18203207.8 +1 more
Examiner
PENG, BO JOSEPH
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Paegasus Médical SA
OA Round
6 (Final)
70%
Grant Probability
Favorable
7-8
OA Rounds
0m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
543 granted / 780 resolved
At TC average
Moderate +14% lift
Without
With
+13.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
46 currently pending
Career history
833
Total Applications
across all art units

Statute-Specific Performance

§101
8.3%
-31.7% vs TC avg
§103
42.3%
+2.3% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 780 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 3 is objected to because of the following informalities: Number for claim 3 is not found. It seems Applicant submitted an error in numbering the claim. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-3, 6-12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner cannot find the term “positioned on an opposite side of said organ,” “altered signals,” “produce altered signals,” and “run algorithms on said altered signals.” Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3, 6-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In re claim 1, it is unclear what the metes and bounds of “altered signals” are. What are altered signals and what are not altered signals? It is unclear what the metes and bounds of “run algorithms on said altered signals” are. Received signals are the ones being obtained. The altered signals as claimed are transmitted signals passed through said organ. These altered signals are NOT yet being detected and merely passed through an organ. How are they being run by algorithms without being detected first? Hence, it is unclear what the metes and bounds of “run algorithms on said altered signals to determine the presence of values below a threshold in the received signal …” are. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BO JOSEPH PENG whose telephone number is (571)270-1792. The examiner can normally be reached Monday thru Friday: 8:00 AM-5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ANNE M KOZAK can be reached at (571) 270-0552. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BO JOSEPH PENG/Primary Examiner, Art Unit 3797
Read full office action

Prosecution Timeline

Show 9 earlier events
Jun 10, 2025
Applicant Interview (Telephonic)
Jun 19, 2025
Response Filed
Aug 21, 2025
Final Rejection mailed — §112
Dec 17, 2025
Request for Continued Examination
Feb 11, 2026
Response after Non-Final Action
Apr 01, 2026
Non-Final Rejection mailed — §112
Jul 01, 2026
Response Filed
Sep 03, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778543
METHOD, A COMPUTER PROGRAM PRODUCT, AND A DEVICE FOR DETERMINING A CROSS-SECTIONAL WIDTH OF AN ARTERY
2y 0m to grant Granted Nov 03, 2026
Patent 12758798
ULTRASOUND AUTOFOCUSING FOR SHORT-PULSE PROCEDURES
2y 5m to grant Granted Oct 13, 2026
Patent 12745978
DEVICE FOR MEASURING OBSTRUCTION OF TRACHEOSTOMY TUBE, TRACHEA, AND BRONCHUS OF PATIENT WITH TRACHEOSTOMY TUBE
2y 1m to grant Granted Sep 29, 2026
Patent 12733991
FLUOROSCOPIC ROBOTIC PROSTHETIC IMPLANT SYSTEM AND METHODS
2y 1m to grant Granted Sep 15, 2026
Patent 12727847
CONTINUOUS BLOOD PRESSURE MEASUREMENT SYSTEM AND METHOD
1y 10m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
70%
Grant Probability
83%
With Interview (+13.7%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 780 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month